One of the strengths of this study lies in its contribution to the limited data available on molecular changes in population across different stages of breast cancer in summary, our results suggest that despite the small sample size, higher levels of PAI-1 and MMP-9 in patients with early-stage breast cancer could be related to a subgroup of patients with a more aggressive evolution. This evidence concerns the gene MMP9 and breast cancer.